Background

Partial sciatic nerve ligation (PSNL) produces axonal damage, a local inflammatory response, and wallerian degeneration. Cytokines secreted near the site of nerve injury are thought to play important roles in development and maintenance of central sensitization and neuropathic pain. Injection of clonidine at the site and time of nerve injury slows the development of PSNL-induced hypersensitivity and reduces local cytokine expression by actions on alpha2 adrenoceptors. The current study tested whether clonidine would have a similar effect in established nerve injury.

Methods

Rats underwent unilateral PSNL, and perineural saline, clonidine, or BRL44408 plus clonidine was injected 2 weeks later. Three days after perineural injection, withdrawal threshold to mechanical stimulation of the hind paw ipsilateral and contralateral to PSNL was determined, and tissues were removed for cytokine analysis.

Results

PSNL was accompanied by a proinflammatory pattern of cytokine content in neural structures and hypersensitivity ipsilaterally with few changes contralaterally. Perineural clonidine, but not saline, partially reversed the hypersensitivity, accompanied by reduced concentrations of interleukin 6 and interleukin 1beta in the sciatic nerve. The effect of clonidine on hypersensitivity and these cytokines was blocked by the alpha2-adrenoceptor antagonist, BRL44408.

Conclusions

These data suggest that perineural clonidine acts on alpha2 adrenoceptors to reduce hypersensitivity in established nerve injury, likely by an immunomodulatory mechanism, and may be effective in patients in the weeks after nerve injury.

INJURY to peripheral nerves provokes an inflammatory response leading to axonal regression and support cell death, a process termed wallerian degeneration . The extent and timing of this response are controlled by the balance between proinflammatory and antiinflammatory cytokine production,1,2which orchestrates nerve demyelination by macrophages and Schwann cells.3,4Interleukin (IL)-1α, IL-1β, IL-6, granulocyte–macrophage colony-stimulating factor, and tumor necrosis factor (TNF)-α are important signaling molecules for the early stages of wallerian degeneration,4,5whereas IL-10 is instrumental in the later healing/regenerative phase.1 

It has been suggested that mechanical hypersensitivity and pain in animals and humans after peripheral nerve injury reflect actions of these cytokines on injured nerves and their central projections.6–10Cytokine production is critical to the initial development and early maintenance of hypersensitivity and central sensitization, including activation of microglia and/or astrocytes in the spinal cord.9–14Central activation of glial cells often results in contralateral hypersensitivity (“mirror-image” pain) in animals,7,10,14which occasionally also occurs in humans.15–17 

Perineural injection of clonidine at the time of surgery delays the onset of hypersensitivity after partial sciatic nerve ligation (PSNL), coincident with reduced TNF-α and IL-1β concentrations in the injured nerve,9and reduces hypersensitivity in established PSNL by actions on α2adrenoceptors.18Cytokine responses after nerve injury change with time, however,1,4and whether the antihypersensitivity effect of perineural clonidine in established PSNL reflects a similar modulation of cytokine responses to that of preemptive treatment is not known.

The purpose of this study was to test the hypothesis that perineural clonidine, by actions on α2adrenoceptors, decreases proinflammatory and/or increases antiinflammatory cytokines in the injured nerve and its central projections in established hypersensitivity after PSNL.

Partial Sciatic Nerve Ligation and Perineural Injections

After approval was obtained from the Animal Care and Use Committee of Wake Forest University Health Sciences Center (Winston-Salem, North Carolina), male Wistar rats (200 g at the time of surgery) underwent partial ligation of the left sciatic nerve (SN) during halothane anesthesia, as previously described with slight modifications.9,19Briefly, the left SN was exposed, and one third to one half of the nerve proximal to the trifurcation of the peroneal, sural, and tibial branches was tightly ligated with silicon-treated silk suture (prolene 6-0). The incision was closed in layers, and animals recovered from anesthesia.

Two weeks after surgery, animals were briefly anesthetized and received a single perineural injection of saline or clonidine, 30 μg, a dose previously shown to reduce mechanical hypersensitivity in this model,9alone or coadministered with BRL44408, 45 μg, an α2A-preferring adrenoceptor antagonist. Injections were administered in a 0.3-ml volume for clonidine and saline alone, or 0.4 ml for clonidine plus BRL44408 using a 25-gauge needle, which was introduced percutaneously between the greater trochanter and the ischial tuberosity and advanced in an anteromedial direction as previously described.9,20Injections were performed in a fanning motion along the path of the SN. Control injections of this volume of ropivacaine in other animals produced temporary unilateral limb paralysis in more than 95% of cases, consistent with reliable delivery of drug near the nerve.

Behavioral Experiments

Animals were placed on a plastic mesh floor in individual plastic boxes for 20–30 min for acclimation. Withdrawal thresholds were assessed using calibrated von Frey filaments (Stoelting, Wood Dale, IL) and an up–down statistical method.21Withdrawal thresholds were measured twice at 10-min intervals, and the average of these was used for analysis. Behavioral testing was performed before surgery, 2 weeks after PSNL (immediately before the perineural injections), and at 5 h and 1, 2, 3, and 7 days after perineural injections. Investigators were blind to treatment groups. Animals in other identical groups received perineural clonidine, saline alone, or clonidine plus BRL44408 and were killed 3 days later for analysis of cytokine concentrations.

Tissue Collection

For tissue collection, animals were anesthetized with halothane and killed by decapitation immediately after the last behavioral test. Four tissues were collected for analysis of cytokine concentrations: L4, L5, and L6 dorsal root ganglia (DRG), combined in each animal, and 0.5-cm sections of the SN proximal to, at, or distal to the injury site. Tissues were collected both ipsilateral and contralateral to the side of injury. We also collected the following tissues from control animals with no surgery or injections: L4, L5, and L6 dorsal root ganglia and SN. Group size was 10–12. All of the samples were collected in 1.5-ml polypropylene tubes (RNAase, DNAase, and pyrogen free) and were put in dry ice immediately after the collection. Subsequently, all of the tissues were stored at −80°C until analysis.

Cytokine Assay

Samples weighing less than 20 mg were combined with 150 μl regular cell culture medium, Roswell Park Memorial Institute (Buffalo, NY) medium plus 10% inactivated bovine serum (Gibco, Grand Island, NY), and samples weighing 20 mg or more were combined with this medium in a ratio of 10 μl/mg tissue. The samples were homogenized in an ice bath with an ultrasonic tissue homogenizer. The homogenates were centrifuged at 1,300g  for 15 min at 4°C; the supernatants were collected and then recentrifuged at 1,500g  for 10 min at 4°C. The supernatants were immediately used for multiplex cytokine assays. Assays were performed in duplicate, and the resultant data were averaged.

A 9-plex bead-based immunoassay kit for rat cytokines (Bio Rad, Hercules, CA) was used to detect the concentrations of granulocyte–macrophage colony-stimulating factor, interferon γ, IL-10, IL-1α, IL-1β, IL-2, IL-4, IL-6, and TNF-α simultaneously, according to the instructions of the manufacturer. This technique has been validated previously.22For the clonidine plus BRL44408 group, only IL-1β and IL-6 were measured. Multiwavelength fluorescence was determined with a luminometer (Luminex 100 system; Luminex, Austin, TX) and analyzed using MasterPlex QT Quantitation Software (MiraiBio, Inc., Alameda, CA).

Concentrations of cytokines in samples were within the linear range of the assay for all cytokines except TNF-α, in which case most samples were below the level of detection (0.2 pg/ml). TNF-α concentrations are therefore not reported.

Statistical Analysis

Data are presented as mean ± SEM. The effects of PSNL surgery and drug injections on withdrawal threshold were determined using a two-way analysis of variance followed by the Dunnett test using pre-PSNL thresholds as control. Comparisons among groups for cytokine concentrations were performed using t  tests or, when normality failed, Mann–Whitney U tests. A P  value less than 0.05 was considered significant for withdrawal threshold. Because we performed a large number of comparisons (eight cytokines in eight tissues), we performed an experiment-wide correction for multiple analyses and considered a P  value of 0.001 or less as significant for each cytokine analysis of variance.

Withdrawal Threshold

Partial sciatic nerve ligation produced a significant decrease in withdrawal threshold ipsilaterally 2 weeks after surgery, and this hypersensitivity was sustained for 7 days in saline-treated animals (P < 0.05; fig. 1). Perineural clonidine partially alleviated hypersensitivity at 2, 3, and 7 days after the injection compared with the saline group (P < 0.05). The maximum effect was seen on day 3 after clonidine treatment (fig. 1). For that reason, other groups of rats were prepared to measure the cytokine levels in the collected tissue 3 days after injection. In those groups, saline did not affect withdrawal threshold (fig. 2A), whereas clonidine partially reversed the hypersensitivity at 2 and 3 days after the injection (P < 0.05; fig. 2A). The effect of clonidine was prevented by BRL44408 (P < 0.05; fig. 2A).

Fig. 1. Withdrawal threshold ipsilateral to injury before and after partial sciatic nerve ligation (PSNL), and after perineural injection of clonidine (  filled circles ) and saline (  open circles ). Each value represents the mean ± SEM of 10 animals. *  P < 0.05 compared with perineural saline treatment. 

Fig. 1. Withdrawal threshold ipsilateral to injury before and after partial sciatic nerve ligation (PSNL), and after perineural injection of clonidine (  filled circles ) and saline (  open circles ). Each value represents the mean ± SEM of 10 animals. *  P < 0.05 compared with perineural saline treatment. 

Close modal

Fig. 2. (  A ) Return of withdrawal threshold to preinjury values after perineural injection of clonidine (  gray bars ), saline (  open bars ), and BRL44408 plus clonidine (  black bars ) administered ipsilateral to partial sciatic nerve injury (PSNL). Each value represents the mean ± SEM of 8–10 animals. *  P < 0.05 compared with perineural saline treatment. +  P < 0.05 compared with perineural clonidine alone treatment. #  P < 0.05 compared with before PSNL. (  B ) Withdrawal threshold contralateral to PSNL in animals treated with perineural injection, on the side ipsilateral to injury, with clonidine (  gray bars ) or saline (  open bars ). Each value represents the mean ± SEM of 10–12 animals. #  P < 0.05 compared with before PSNL. 

Fig. 2. (  A ) Return of withdrawal threshold to preinjury values after perineural injection of clonidine (  gray bars ), saline (  open bars ), and BRL44408 plus clonidine (  black bars ) administered ipsilateral to partial sciatic nerve injury (PSNL). Each value represents the mean ± SEM of 8–10 animals. *  P < 0.05 compared with perineural saline treatment. +  P < 0.05 compared with perineural clonidine alone treatment. #  P < 0.05 compared with before PSNL. (  B ) Withdrawal threshold contralateral to PSNL in animals treated with perineural injection, on the side ipsilateral to injury, with clonidine (  gray bars ) or saline (  open bars ). Each value represents the mean ± SEM of 10–12 animals. #  P < 0.05 compared with before PSNL. 

Close modal

Partial sciatic nerve ligation produced a slight but significant decrease of withdrawal threshold contralaterally to the injury. Perineural saline or clonidine injection, ipsilateral to the injury, did not affect the withdrawal thresholds contralaterally (fig. 2B).

Effect of PSNL on Cytokine Concentration

Partial sciatic nerve ligation increased IL-1β, IL-2, and IL-6 in DRG (P ≤ 0.001; fig. 3), as well as IL-10 and IL-6 in the SN proximal to injury (P ≤ 0.001; fig. 3). Distal to injury, only IL-1β increased (P ≤ 0.001; fig. 3).

Fig. 3. Cytokine concentrations in normal (Nl) animals or those ipsilateral to partial sciatic nerve injury followed by perineural saline (Sal), clonidine (Clo), or clonidine plus BRL44408 (BR+Clo) 3 days before tissue harvest.  Top panel depicts dorsal root ganglia (DRG) tissues, and  bottom panel depicts sciatic nerve (SN) tissue, referenced to the site of injury. Each bar represents the mean ± SEM of 10–12 animals. *  P ≤ 0.001 compared with normal tissue. +  P ≤ 0.001 compared with saline treatment. #  P ≤ 0.001 compared with clonidine treatment. IL = interleukin. 

Fig. 3. Cytokine concentrations in normal (Nl) animals or those ipsilateral to partial sciatic nerve injury followed by perineural saline (Sal), clonidine (Clo), or clonidine plus BRL44408 (BR+Clo) 3 days before tissue harvest.  Top panel depicts dorsal root ganglia (DRG) tissues, and  bottom panel depicts sciatic nerve (SN) tissue, referenced to the site of injury. Each bar represents the mean ± SEM of 10–12 animals. *  P ≤ 0.001 compared with normal tissue. +  P ≤ 0.001 compared with saline treatment. #  P ≤ 0.001 compared with clonidine treatment. IL = interleukin. 

Close modal

Contralaterally, we observed that IL-1β and IL-6 were increased in proximal SN, as well as the antiinflammatory cytokine IL-10 in mid and distal SN (P ≤ 0.001; fig. 4).

Fig. 4. Cytokine concentrations in sciatic nerve sections from normal (Nl) animals or those contralateral to partial sciatic nerve injury followed by perineural saline (Sal) or clonidine (Clo) 3 days before tissue harvest. Each bar represents the mean ± SEM of 10–12 animals. *  P ≤ 0.001 compared with normal tissue. IL = interleukin. 

Fig. 4. Cytokine concentrations in sciatic nerve sections from normal (Nl) animals or those contralateral to partial sciatic nerve injury followed by perineural saline (Sal) or clonidine (Clo) 3 days before tissue harvest. Each bar represents the mean ± SEM of 10–12 animals. *  P ≤ 0.001 compared with normal tissue. IL = interleukin. 

Close modal

Effects of Perineural Clonidine on Cytokine Concentrations

Compared with perineural saline, clonidine injection 3 days before tissue harvest was associated with significantly decreased concentrations of IL-6 in ipsilateral SN proximal to injury and IL-1β in ipsilateral SN distal to injury (P ≤ 0.001; fig. 3). Clonidine did not otherwise affect cytokine concentrations ipsilateral to PSNL, including a lack of effect of the increased IL-10 concentrations in the injured SN (fig. 3), and did not affect cytokine concentrations contralateral to PSNL (fig. 4). BRL44408 prevented clonidine-associated decreases in IL-1β in ipsilateral DRG and IL-6 in both ipsilateral DRG and SN distal to injury (P ≤ 0.001; fig. 3).

The role of cytokine production and signaling in the pathogenesis of nerve injury and pain is of current interest. Acute administration of the proinflammatory cytokines, which are present shortly after injury, into normal peripheral nerve or tissues sensitizes afferents and results in hypersensitivity.23Although the role of cytokines in pain and hypersensitivity may well diminish over time after injury, the current study suggests that they are important factors as long as 2 weeks after surgical nerve injury and can be modified at this time by perineural clonidine.

Cytokine Expression 2 Weeks after PSNL

Four cytokines, IL-1β, IL-2, IL-6, and IL-10, were increased in ipsilateral tissues 2 weeks after PSNL in the current study. These results confirm previous observations of increased IL-1β and IL-6 late after nerve injury.4,5Cell types important to production of these cytokines in this setting include macrophages, mast cells, and lymphocytes. These cytokines have been described as pronociceptive8,14,23–25and are speculated to be important determinants of hypersensitivity at this time. IL-10 is an antiinflammatory cytokine with increased expression late after nerve injury, presumably to initiate regeneration of the damaged nerves. IL-10 down-regulates expression of the major proinflammatory cytokines.1As part of the balance of normal inflammatory processes, proinflammatory cytokines themselves increase IL-10 expression.26Therefore, we speculate that increased IL-10 concentrations observed in the current study are secondary to previously increased proinflammatory cytokines and may be signaling regeneration 2 weeks after injury. IL-2 is a key factor in activation of the innate immune system27,28and exerts antinociceptive effects.29–32IL-2 concentration is increased in plasma beginning on day 11 after nerve injury in rats33and may be important in regeneration of transected nerve.34 

Others have observed changes in cytokine messenger RNA expression in neural structures contralateral to peripheral nerve transsection.35We observed a strikingly similar pattern of cytokine expression in contralateral DRG and SN as that ipsilateral to PSNL injury. Thus, there was a bilateral increase in IL-1β, IL-6, and IL-10, although the proinflammatory cytokines IL-1β and IL-6 were numerically increased less contralaterally than ipsilaterally, and the antiinflammatory cytokine IL-10 was numerically increased more. This suggests that contralateral changes in cytokine concentrations are not merely a systemic response to injury but are regionally controlled. Others have proposed a communication of activity or transport of chemicals as a mechanism to explain contralateral changes in unilateral neuropathies.36,37Certainly, microglial activation, perhaps via  gap junctions, may contribute to the mirror-image hypersensitivity observed after unilateral neuritis.38 

Tumor necrosis factor α is markedly increased in injured peripheral nerve for 3–7 days and likely plays an important role in hypersensitivity during this period.9Because the sensitivity of our methodology to detect TNF-α was inadequate, the current study did not address the relevance of this key cytokine 2 weeks after PSNL.

Effects of Clonidine

Perineural injection of clonidine reduces hypersensitivity weeks after PSNL in rats.18Because that study observed α2-adrenoceptor immunoreactivity in macrophages and T cells in the injured nerve, it was presumed that clonidine was altering immune cell function to produce its delayed-onset, prolonged effect. Subsequently, repeated perineural clonidine injections at the time of PSNL injury were shown to delay the development of hypersensitivity, accompanied by significant reductions in TNF-α and IL-1β concentrations in clonidine-treated animals.9In addition, different cytokines, particularly IL-6 and IL-2, were increased in addition to IL-1β 2 weeks after PSNL, consistent with the changing cytokine expression profile accompanying wallerian degeneration.4,33Two observations argue for an immunomodulatory effect of clonidine to reduce hypersensitivity: similar time course of behavioral and immunologic effects and presence of α2-adrenoceptors on immune cells at the site of injury.18 

The blockade of the behavioral effect of clonidine confirms previous observations9,18that clonidine is acting on α2adrenoceptors. More importantly, parallel blockade of clonidine’s reduction of IL-1β and IL-6 as well as its antihypersensitivity effect by BRL44408 strongly supports an immunomodulatory mechanism of action of clonidine for analgesia in this setting.

The mechanisms by which perineural clonidine alters hypersensitivity and cytokine expression after nerve injury are uncertain, although they clearly involve actions on α2adrenoceptors. The current study indicates that cytokine expression is reduced days after a single clonidine injection, and we speculate that clonidine acutely altered genetic expression which subsequently changed immune or neural cell phenotype. This speculation is supported by reduction in abnormal excitability in injured afferents days after a single perineural injection of clonidine39and reduction in cytokine expression and response to immune challenge in leukocytes 3 days after a single perineural injection of clonidine in a model of inflammatory sciatic neuritis.40 

Although others have demonstrated excitatory α2adrenoceptors on injured nociceptiors,41there are no reports of clonidine-induced pain, and animals in the current study did not demonstrate agitation behavior after perineural clonidine. In addition, other manipulations that reduce IL-1 or IL-6 or increase IL-1014reduce hypersensitivity in settings of nerve injury or inflammation, arguing for a causal relation between clonidine-induced reduction in IL-1β and IL-6 and its antihypersensitivity effect.

In conclusion, 2 weeks after PSNL injury, there is a different pattern of cytokine expression ipsilateral to nerve injury than closer to the time of injury, with some changes contralaterally. Perineural clonidine partially alleviates mechanical hypersensitivity at this time, and we speculate that this is secondary to reduced cytokine expression, because both the analgesic and cytokine modulation effects of perineural clonidine are similarly blocked by an α2-adrenoceptor antagonist. These data provide the rationale for clinical trials examining the efficacy of perineural clonidine for patients with pain and hypersensitivity shortly after traumatic nerve injury, such as occurs commonly after surgery.

The authors thank Carine Dalle, Ph.D. (Department of Anesthesiology, Wake Forest University School of Medicine, Winston-Salem, North Carolina), for assistance in the perineural injection technique.

1.
Be’eri H, Reichert F, Saada A, Rotshenker S: The cytokine network of wallerian degeneration: IL-10 and GM-CSF. Eur J Neurosci 1998; 10:2707–13
2.
Franzen R, Bouhy D, Schoenen J: Nervous system injury: Focus on the inflammatory cytokine “granulocyte-macrophage colony stimulating factor.” Neurosci Lett 2004; 361:76–8
3.
Reichert F, Saada A, Rotshenker S: Peripheral nerve injury induces Schwann cells to express two macrophage phenotypes: Phagocytosis and the galactose-specific lectin MAC-2. J Neurosci 1994; 14:3231–45
4.
Shamash S, Reichert F, Rotshenker S: The cytokine network of Wallerian degeneration: Tumor necrosis factor-alpha, interleukin-1alpha, and interleukin-1beta. J Neurosci 2002; 22:3052–60
5.
Reichert F, Levitzky R, Rotshenker S: Interleukin 6 in intact and injured mouse peripheral nerves. Eur J Neurosci 1996; 8:530–5
6.
Chacur M, Milligan ED, Gazda LS, Armstrong C, Wang H, Tracey KJ, Maier SF, Watkins LR: A new model of sciatic inflammatory neuritis (SIN): Induction of unilateral and bilateral mechanical allodynia following acute unilateral peri-sciatic immune activation in rats. Pain 2001; 94:231–44
7.
Milligan ED, Twining C, Chacur M, Biedenkapp J, O’Connor K, Poole S, Tracey K, Martin D, Maier SF, Watkins LR: Spinal glia and proinflammatory cytokines mediate mirror-image neuropathic pain in rats. J Neurosci 2003; 23:1026–40
8.
Lindenlaub T, Sommer C: Cytokines in sural nerve biopsies from inflammatory and non-inflammatory neuropathies. Acta Neuropathol (Berl) 2003; 105:593–602
9.
Lavand’homme PM, Eisenach JC: Perioperative administration of the alpha2-adrenoceptor agonist clonidine at the site of nerve injury reduces the development of mechanical hypersensitivity and modulates local cytokine expression. Pain 2003; 105:247–54
10.
Raghavendra V, Tanga FY, DeLeo JA: Complete Freunds adjuvant-induced peripheral inflammation evokes glial activation and proinflammatory cytokine expression in the CNS. Eur J Neurosci 2004; 20:467–73
11.
Jin SX, Zhuang ZY, Woolf CJ, Ji RR: p38 mitogen-activated protein kinase is activated after a spinal nerve ligation in spinal cord microglia and dorsal root ganglion neurons and contributes to the generation of neuropathic pain. J Neurosci 2003; 23:4017–22
12.
Tsuda M, Mizokoshi A, Shigemoto-Mogami Y, Koizumi S, Inoue K: Activation of p38 mitogen-activated protein kinase in spinal hyperactive microglia contributes to pain hypersensitivity following peripheral nerve injury. Glia 2004; 45:89–95
13.
Tanga FY, Raghavendra V, DeLeo JA: Quantitative real-time RT-PCR assessment of spinal microglial and astrocytic activation markers in a rat model of neuropathic pain. Neurochem Int 2004; 45:397–407
14.
Twining CM, Sloane EM, Milligan ED, Chacur M, Martin D, Poole S, Marsh H, Maier SF, Watkins LR: Peri-sciatic proinflammatory cytokines, reactive oxygen species, and complement induce mirror-image neuropathic pain in rats. Pain 2004; 110:299–309
15.
Oaklander AL, Belzberg AJ: Unilateral nerve injury down-regulates mRNA for Na+ channel SCN10A bilaterally in rat dorsal root ganglia. Brain Res Mol Brain Res 1997; 52:162–5
16.
Oaklander AL, Romans K, Horasek S, Stocks A, Hauer P, Meyer RA: Unilateral postherpetic neuralgia is associated with bilateral sensory neuron damage. Ann Neurol 1998; 44:789–95
17.
Oaklander AL, Brown JM: Unilateral nerve injury produces bilateral loss of distal innervation. Ann Neurol 2004; 55:639–44
18.
Lavand’homme PM, Ma W, De Kock M, Eisenach JC: Perineural alpha(2A)-adrenoceptor activation inhibits spinal cord neuroplasticity and tactile allodynia after nerve injury. Anesthesiology 2002; 97:972–80
19.
Seltzer Z, Dubner R, Shir Y: A novel behavioral model of neuropathic pain disorders produced in rats by partial sciatic nerve injury. Pain 1990; 43:205–18
20.
Thalhammer JG, Vladimirova M, Bershadsky B, Strichartz GR: Neurologic evaluation of the rat during sciatic nerve block with lidocaine. Anesthesiology 1995; 82:1013–25
21.
Chaplan SR, Bach FW, Pogrel JW, Chung JM, Yaksh TL: Quantitative assessment of tactile allodynia in the rat paw. J Neurosci Methods 1994; 53:55–63
22.
Hulse RE, Kunkler PE, Fedynyshyn JP, Kraig RP: Optimization of multiplexed bead-based cytokine immunoassays for rat serum and brain tissue. J Neurosci Methods 2004; 136:87–98
23.
Sachs D, Cunha FQ, Poole S, Ferreira SH: Tumour necrosis factor-alpha, interleukin-1beta and interleukin-8 induce persistent mechanical nociceptor hypersensitivity. Pain 2002; 96:89–97
24.
Ferreira SH, Lorenzetti BB, Bristow AF, Poole S: Interleukin-1 beta as a potent hyperalgesic agent antagonized by a tripeptide analogue. Nature 1988; 334:698–700
25.
DeLeo JA, Colburn RW, Nichols M, Malhotra A: Interleukin-6-mediated hyperalgesia/allodynia and increased spinal IL-6 expression in a rat mononeuropathy model. J Interferon Cytokine Res 1996; 6:695–700
26.
de Waal Malefyt R: IL-10, Cytokine Reference. Edited by Oppenhheim JJ, Feldman M. New York, Academic, 2001, pp 165–85Oppenhheim JJ, Feldman M
New York
,
Academic
27.
Granucci F, Zanoni I, Feau S, Ricciardi-Castagnoli P: Dendritic cell regulation of immune responses: A new role for interleukin 2 at the intersection of innate and adaptive immunity. EMBO J 2003; 22:2546–51
28.
Granucci F, Feau S, Zanoni I, Pavelka N, Vizzardelli C, Raimondi G, Ricciardi-Castagnoli P: The immune response is initiated by dendritic cells via interaction with microorganisms and interleukin-2 production. J Infect Dis 2003; 187:S346–50
29.
Guo H, Zhao ZQ: Inhibition of nociceptive withdrawal reflex by microinjection of interleukin 2 into rat locus coeruleus. Neuropeptides 2000; 34:216–20
30.
Song P, Zhao Z: Interleukin 2-induced antinociception partially coupled with mu receptor. Cytokine 2000; 12:1240–2
31.
Yao MZ, Gu JF, Wang JH, Sun LY, Lang MF, Liu J, Zhao ZQ, Liu XY: Interleukin-2 gene therapy of chronic neuropathic pain. Neuroscience 2002; 112:409–16
32.
Yao MZ, Gu JF, Wang JH, Sun LY, Liu H, Liu XY: Adenovirus-mediated interleukin-2 gene therapy of nociception. Gene Ther 2003; 10:1392–9
33.
Wells MR, Racis Jr, SP Vaidya U: Changes in plasma cytokines associated with peripheral nerve injury. J Neuroimmunol 1992; 39:261–8
34.
Petitto JM, Huang Z, Lo J, Streit WJ: IL-2 gene knockout affects T lymphocyte trafficking and the microglial response to regenerating facial motor neurons. J Neuroimmunol 2003; 134:95–103
35.
Ruohonen S, Jagodi M, Khademi M, Taskinen HS, Ojala P, Olsson T, Roytta M: Contralateral non-operated nerve to transected rat sciatic nerve shows increased expression of IL-1beta, TGF-beta1, TNF-alpha, and IL-10. J Neuroimmunol 2002; 132:11–7
36.
Koltzenburg M, Wall PD, McMahon SB: Does the right side know what the left is doing? Trends Neurosci 1999; 22:122–7
37.
Lowrie MB: Contralateral effects of peripheral nerve injury (letter). Trends Neurosci 1999; 22:496–7
38.
Spataro LE, Sloane EM, Milligan ED, Wieseler-Frank J, Schoeniger D, Jekich BM, Barrientos RM, Maier SF, Watkins LR: Spinal gap junctions: Potential involvement in pain facilitation. J Pain 2004; 5:392–405
39.
Liu B, Eisenach JC: Hyperexcitability of axotomized and neighboring unaxotomized sensory neurons is reduced days after perineural clonidine at the site of injury. J Neurophysiol 2005; 94:3159–67
40.
Romero-Sandoval EA, McCall C, Eisenach JC: α2-Adrenoceptor stimulation transforms immune responses in neuritis and blocks neuritis induced pain. J Neurosci 2005; 25:8988–94
41.
Sato J, Perl ER: Adrenergic excitation of cutaneous pain receptors induced by peripheral nerve injury. Science 1991; 251:1608–10